Search Results

CSL's approach to community contributions is guided by our Code of Responsible Business Practice and Global Community Contributions Policy.

https://corporateresponsibility.csl.com/community

CSL regards stakeholder engagement as a foundation of corporate responsibility, and have identified our key stakeholders as patient groups, employees, investors, regulators, suppliers, government, healthcare professionals, plasma donors, business partners and the academic and scientific community.

https://corporateresponsibility.csl.com/approach/stakeholder-engagement

At CSL, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities.

https://corporateresponsibility.csl.com/

Read about CSL's approach to stakeholder engagement and review a summary of our performance in key areas such as innovation, safety and quality, community, and environment.

https://corporateresponsibility.csl.com/approach

In Australia, CSL contributes to a range of public policy debates in which we have expertise including biopharmaceuticals, medical research, patient advocacy and more.

https://corporateresponsibility.csl.com/marketplace/public-policy/australian-initiatives

I encourage you to review our Code to understand how it impacts your role and the way in which you represent CSL in business and the broader community.

https://corporateresponsibility.csl.com/-/media/csl/documents/crbp-languages/csl_crbp2021_english_external.pdf

CSL is committed to the development, manufacture and supply of high quality, safe products that save lives and improve the health and wellbeing of patients with serious diseases.

https://corporateresponsibility.csl.com/safety/plasma-therapies-and-vaccines

CSL has an active program of supplier selection and management. In many cases, the selection of suppliers is primarily driven by stringent quality, regulatory or reliability constraints.

https://corporateresponsibility.csl.com/safety/supplier-management

CSL’s Global CR Committee has overall responsibility for the materiality process and executes a global materiality assessment on a biennial basis. In 2017/18, we concluded our third such assessment and followed the Global Reporting Initiative (GRI) standards of sustainability context, materiality, completeness and stakeholder inclusiveness through our process of identification, review and prioritisation. The application and disclosure of our materiality process against the GRI materiality principle definition was externally assured by Ernst & Young.

https://corporateresponsibility.csl.com/approach/material-topics

We act lawfully, honestly and fairly when competing in the market, and strive to fulfil our responsibilities to shareholders while facilitating access to our therapies for patients.

https://corporateresponsibility.csl.com/marketplace/competition-and-pricing